Phase I- II Study of in Vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for the Treatment of Steroid-refractory Acute Graft-versus-host Disease

Trial Profile

Phase I- II Study of in Vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for the Treatment of Steroid-refractory Acute Graft-versus-host Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2013

At a glance

  • Drugs Azacitidine (Primary) ; Interleukin-2 (Primary) ; Cyclophosphamide; Sirolimus
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top